6xv7
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 2== | ==CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 2== | ||
| - | <StructureSection load='6xv7' size='340' side='right'caption='[[6xv7]]' scene=''> | + | <StructureSection load='6xv7' size='340' side='right'caption='[[6xv7]], [[Resolution|resolution]] 1.67Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XV7 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6XV7 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6xv7]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XV7 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6XV7 FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6xv7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xv7 OCA], [http://pdbe.org/6xv7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6xv7 RCSB], [http://www.ebi.ac.uk/pdbsum/6xv7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6xv7 ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=O2Q:~{N}-[[3,4-bis(fluoranyl)phenyl]methyl]-~{N},3-dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-6-amine'>O2Q</scene></td></tr> |
| + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6xuz|6xuz]], [[6xv3|6xv3]]</td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">BRD4, HUNK1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6xv7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xv7 OCA], [http://pdbe.org/6xv7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6xv7 RCSB], [http://www.ebi.ac.uk/pdbsum/6xv7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6xv7 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | == Disease == | ||
| + | [[http://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein.<ref>PMID:12543779</ref> <ref>PMID:11733348</ref> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN]] Plays a role in a process governing chromosomal dynamics during mitosis (By similarity). | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | While CH-pi-interactions with target proteins are crucial determinants for the affinity of arguably every drug molecule, no method exists to directly measure the strength of individual CH-pi interactions in drug-protein complexes. Here we present a fast and reliable methodology called PI (pi interactions) by NMR, which can differentiate the strength of protein-ligand CH-pi interactions in solution. By combining selective amino-acid side-chain labeling with 1 H- 13 C NMR, we are able to identify specific protein protons of side-chains engaged in CH-pi interactions with aromatic ring-systems of a ligand, based solely on 1 H chemical shift values of the interacting protein aromatic ring protons. The information encoded in the chemical shifts induced by such interactions serves as a proxy for the strength of each individual CH-pi interaction. PI by NMR changes the paradigm by which chemists can optimize the potency of drug candidates: direct determination of individual pi-interactions rather than averaged measures of all interactions. | ||
| + | |||
| + | PI by NMR: Probing CH-pi Interactions in Protein-Ligand Complexes by NMR.,Platzer G, Mayer M, Beier A, Bruschweiler S, Fuchs JE, Engelhardt H, Geist L, Bader G, Schorghuber J, Lichtenecker R, Wolkersdorfer B, Kessler D, McConnell DB, Konrat R Angew Chem Int Ed Engl. 2020 May 18. doi: 10.1002/anie.202003732. PMID:32421895<ref>PMID:32421895</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6xv7" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Human]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Bader G]] | + | [[Category: Bader, G]] |
| - | [[Category: Kessler D]] | + | [[Category: Kessler, D]] |
| - | [[Category: Wolkerstorfer B]] | + | [[Category: Wolkerstorfer, B]] |
| + | [[Category: Bromodomain]] | ||
| + | [[Category: Complex]] | ||
| + | [[Category: Inhibitor]] | ||
| + | [[Category: Transcription]] | ||
Revision as of 11:46, 22 July 2020
CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 2
| |||||||||||
